Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Episode 1 February 28, 2022 00:13:11
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022
COR2ED Medical Education
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Feb 28 2022 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode 1

May 03, 2022 00:22:30
Episode Cover

Immune tolerance induction in the era of emicizumab

COR2ED Medical Education: In this podcast, two haematology experts discuss their views on the use of immune tolerance induction (ITI) in haemophilia. Prof. Jan...

Listen

Episode 1

November 18, 2022 00:32:39
Episode Cover

The role of SSA at progression – to continue or not?

COR2ED Medical Education: In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether...

Listen

Episode 1

February 15, 2023 00:21:50
Episode Cover

Clinical implementation of PARPi monotherapy for prostate cancer patients – a US and EU perspective

COR2ED Medical Education: Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and...

Listen